Rep. Byron Donalds Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares

Representative Byron Donalds (R-Florida) recently sold shares of Regeneron Pharmaceuticals, Inc. NASDAQ: REGN. In a filing disclosed on May 24th, the Representative disclosed that they had sold between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on April 10th. The trade occurred in the Representative's "MORAN WEALTH IRA" account.

• Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025

Representative Byron Donalds also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 4/10/2025.
• Sold $1,001 - $15,000 in shares of NU NYSE: NU on 4/10/2025.
• Purchased $1,001 - $15,000 in shares of Amphenol NYSE: APH on 4/10/2025.
• Sold $1,001 - $15,000 in shares of Equifax NYSE: EFX on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of Chipotle Mexican Grill NYSE: CMG on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Gartner NYSE: IT on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Robinhood Markets NASDAQ: HOOD on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of Arista Networks NYSE: ANET on 3/20/2025.
• Sold $1,001 - $15,000 in shares of GoDaddy NYSE: GDDY on 3/20/2025.

Regeneron Pharmaceuticals Stock Up 2.5%

REGN opened at $603.26 on Wednesday. The business's fifty day moving average is $589.51 and its two-hundred day moving average is $671.75. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market cap of $65.13 billion, a price-to-earnings ratio of 15.76, a PEG ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a one year low of $520.50 and a one year high of $1,211.20.

• Best Biotech Stocks to Buy in 2025

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $9.55 earnings per share. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.58%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

• 3 Stocks With Ironclad Balance Sheets for Long-Term Stability

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pinney & Scofield Inc. acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. Rakuten Securities Inc. increased its stake in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the last quarter. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $28,000. E Fund Management Hong Kong Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares during the last quarter. Finally, Activest Wealth Management grew its stake in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REGN has been the subject of a number of analyst reports. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target for the company. Citigroup raised Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $600.00 to $700.00 in a report on Wednesday, May 14th. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Finally, Bank of America cut their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $890.60.

View Our Latest Report on Regeneron Pharmaceuticals

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida's 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida's 19th Congressional District. He declared candidacy for the 2026 election. Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor's degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

See Also

• Five stocks we like better than Regeneron Pharmaceuticals
• The Risks of Owning Bonds
• 3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
• What is Insider Trading? What You Can Learn from Insider Trading
• Tesla: Why Analysts Think It Could Jump Another 47%
• The How And Why of Investing in Oil Stocks
• Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here